We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

29 hedge funds and large institutions have $37.4M invested in Palvella Therapeutics in 2016 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

100% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 4

18% more capital invested

Capital invested by funds: $31.7M → $37.4M (+$5.71M)

12% more funds holding

Funds holding: 26 → 29 (+3)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
29
Holders Change
+3
Holders Change %
+11.54%
% of All Funds
0.77%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
7
Increased
8
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BI
BVF Inc
California
+$1.29M
2
TCM
Tekla Capital Management
Massachusetts
+$495K
3
Morgan Stanley
Morgan Stanley
New York
+$123K
4
Renaissance Technologies
Renaissance Technologies
New York
+$71.6K
5
Deutsche Bank
Deutsche Bank
Germany
+$57.5K

Top Sellers

1
OFM
Omega Fund Management
Massachusetts
-$687K
2
SM
Sabby Management
Florida
-$121K
3
FWM
Frontier Wealth Management
Missouri
-$99.7K
4
VKH
Virtu KCG Holdings
New York
-$20K
5
TC
TFS Capital
Pennsylvania
-$17K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$13.3M – – –
TCM
2
Tekla Capital Management
Massachusetts
$7.59M +$495K +3,722 +8%
LOAMU
3
Lombard Odier Asset Management (USA)
New York
$5.79M – – –
OFM
4
Omega Fund Management
Massachusetts
$3.38M -$687K -5,173 -18%
SM
5
Sabby Management
Florida
$2.82M -$121K -909 -5%
BI
6
BVF Inc
California
$1.86M +$1.29M +9,690 +321%
SFM
7
Sphera Funds Management
Israel
$1.48M – – –
DCM
8
DAFNA Capital Management
California
$408K – – –
Morgan Stanley
9
Morgan Stanley
New York
$136K +$123K +928 +92,800%
BFA
10
BlackRock Fund Advisors
California
$127K -$1.2K -9 -1%
Renaissance Technologies
11
Renaissance Technologies
New York
$79K +$71.6K +539 New
Deutsche Bank
12
Deutsche Bank
Germany
$63K +$57.5K +433 New
RJA
13
Raymond James & Associates
Florida
$55K +$49.8K +375 New
FWM
14
Frontier Wealth Management
Missouri
$46K -$99.7K -750 -71%
Northern Trust
15
Northern Trust
Illinois
$46K +$41.6K +313 New
Creative Planning
16
Creative Planning
Kansas
$37K +$24.9K +187 +297%
PAM
17
Panagora Asset Management
Massachusetts
$37K +$33.4K +251 New
Millennium Management
18
Millennium Management
New York
$33K +$8.51K +64 +39%
Bank of America
19
Bank of America
North Carolina
$32K +$4.12K +31 +16%
JP Morgan Chase
20
JP Morgan Chase
New York
$32K +$29.1K +219 New
OC
21
Oppenheimer & Co
New York
$27K – – –
Geode Capital Management
22
Geode Capital Management
Massachusetts
$23K – – –
BIT
23
BlackRock Institutional Trust
California
$22K – – –
LAM
24
Lebenthal Asset Management
New York
$18K – – –
BIM
25
BlackRock Investment Management
Delaware
$10K +$797 +6 +9%
1
2

PVLA Hedge Fund Activity: Q3 2016 in Review

29 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q3 2016, worth a combined $37.4M — up 18% from $31.7M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new PVLA positions and 3 closed out — a net gain of 4 holders — while 8 added to existing stakes and 4 trimmed.

The largest buyer was BVF Inc, adding an estimated $1.29M. The largest seller was Omega Fund Management, cutting an estimated $687K.

  • 29 institutional investors held Palvella Therapeutics (PVLA) as of Q3 2016, up from 26 in Q2 2016.
  • Funds reported $37.4M of Palvella Therapeutics stock for Q3 2016, up 18% quarter-over-quarter.
  • 7 funds opened new Palvella Therapeutics positions in Q3 2016 and 3 closed out, a net change of +4 holders.
  • The largest Palvella Therapeutics buyer in Q3 2016 was BVF Inc, an estimated $1.29M added.
  • The largest Palvella Therapeutics seller in Q3 2016 was Omega Fund Management, an estimated $687K sold.

Based on aggregated 13F filings for Q3 2016.